INVESTMENT SECURITIES (Details) - USD ($)	6 Months Ended
Mar. 31, 2022	Sep. 30, 2021
Available-for-sale Securities	$ 67,710	$ 198,006
Common Stock [Member] \| Oncology Pharma [Member]
Investment Securities, Basis	677,100
Available-for-sale Securities	67,710
Investment Securities, Total Unrealized Gain	602,985
Equity Securities, FV-NI, Unrealized Gain (Loss)	$ (123,891)

Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(3)(d))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 321
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=123583765&loc=SL75117546-209714

Name:	us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration